Microbial Infections and Cancer Therapy  book cover
1st Edition

Microbial Infections and Cancer Therapy

ISBN 9789814774864
Published February 13, 2019 by Jenny Stanford Publishing
464 Pages

USD $179.95

Prices & shipping based on shipping country


Book Description

This book deals with the emerging concept that certain pathogenic bacteria and viruses, when infecting people with cancer, actively fight tumors, allowing their regression. Although such observations go back more than 100 years, use of specific bacterial strains, or viruses, usually genetically modified with known anticancer drugs, and their protein/peptide products, has gained ground in recent years, allowing significant cancer regression in clinical trials with stage III/IV cancer patients or even in pediatric brain tumor patients, often without any demonstration of toxicity. It is composed of 12 chapters written by pioneers in microbial, biotech, and cancer research and covers the emerging roles of various microorganisms and their products in cancer therapy. The book highlights the benefits of using conventional cancer treatments (such as chemo- and radiotherapies) with microbial-based therapies. Such combinatorial therapies have gained particular attention as a strategy to overcome drug resistance, and the readers of the book will discover their impact on fundamental research and promising results from clinical trials.

Table of Contents

Bifidobacterium as a Delivery System of Functional Gene for Cancer Gene Therapy

Chao Han, Yu-qing Dai, Zi-chun Hua, Geng-Feng Fu, Yan Yin, Bi Hu, and Gen-xing Xu

Therapy with Oncolytic Clostridium novyi-NT: From Mice to Men

Shibin Zhou

Genetic Engineering of Clostridial Strains for Cancer Therapy

Maria Zygouropoulou, Aleksandra Kubiak, Adam V. Patterson, and Nigel P. Minton

Bacteria-Derived Alternatives to Live Mycobacterium bovis Bacillus Calmette-Guerin for Non-Muscle Invasive Bladder Cancer Treatment

Esther Julián and Estela Noguera-Ortega

Genetically Modified Salmonella as Cancer Therapeutics: Mechanisms, Advances and Challenges

Xiaoxin Zhang and Zi-Chun Hua

Genetically Engineered Oncolytic Salmonella typhimurium

Jin Hai Zheng and Jung-Joon Min

Engineering E. coli to Combat Cancer

Carlos Piñero-Lambea, David Ruano-Gallego, Gustavo Bodelón, Beatriz Álvarez, and Luis Ángel Fernández

Live P. aeruginosa as Cancer Vaccine Vector

Y. Wang, B. Polack, and B. Toussaint

The Anticancer Potential of the Bacterial Protein Azurin and Its Derived Peptide P28

Ana Rita Garizo, Nuno Bernardes, Ananda M. Chakrabarty, and Arsénio M. Fialho

Bacteriocins: From Antimicrobial to Potencial Anticancer Agents

Lígia Coelho, Nuno Bernardes, and Arsénio M. Fialho

Bacteriocins as Anticancer Peptides? A Biophysical Approach

Filipa Dias de Oliveira, Miguel A. R. B. Castanho, and Diana Gaspar

Where Cancer and Bacteria Meet

Alexandra Merlos, Ricardo Perez-Tomás, José López-López, and Miguel Viñas

View More



Arsénio M. Fialho is associate professor in the Bioengineering Department of Instituto Superior Técnico and principal investigator in the Biological Science Research Group, Institute for Bioengineering and Biosciences, at the University of Lisbon, Lisbon, Portugal. His teaching and research interests are in molecular and cellular biology. His research focuses on the study of bacterial proteins/peptides as novel drug candidates for cancer therapy and aims to elucidate the cellular and molecular effects of treating cancer cell models with the protein azurin and its fragment, a cell-penetrating peptide of 28 amino acids known as p28. The p28 peptide successfully completed two phase I clinical trials in the United States. Prof. Fialho is also interested in the development of nanocarriers for anticancer drugs and study of trimeric autotransporter adhesins as novel and key virulence determinants in members of the Burkholderia cepacia complex. He serves as an expert for several national and international funding agencies and organizations. He has authored of 75 articles in peer-reviewed scientific journals, 2 books, and 13 book chapters and holds 8 US patents.

Ananda M. Chakrabarty is a distinguished university professor of microbiology and immunology at the University of Illinois College of Medicine and advises senior officials in the United States and abroad on the policies relating to biotechnology and associated technology transfer. As a consultant to the United Nations, he was on the advisory committee that resulted in the creation of the International Center for Genetic Engineering and Biotechnology in Trieste, Italy. In 1980, Dr. Chakrabarty’s genetically modified Pseudomonas bacteria became the first genetically engineered organism to gain a patent, as a result of the Supreme Court decision in Diamond v. Chakrabarty. He has continued to undertake pioneering biotechnology research into the therapeutic potential for protein products of bacteria, both at the University of Illinois at Chicago and on behalf of CDG Therapeutics (USA) and Amrita Therapeutics (India), two biotechnology start-ups engaged in clinical cancer research. Dr. Chakrabarty has more than 280 research publications to his credit and has received many notable international awards for his contributions to biotechnology.